Oral eltanexor treatment of patients with higher-risk myelodysplastic syndrome refractory to hypomethylating agents.
Autorzy:
Lee S; Division of Hematology and Oncology, Weill Cornell Medicine, The New York Presbyterian Hospital, 520 East 70thStreet, Starr 341, New York, NY, 10021, USA. .; Janssen Research and Development, Spring House, PA, USA. . Mohan S; Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN, USA. Knupp J; Karyopharm Therapeutics Inc, Newton, MA, USA. Chamoun K; Karyopharm Therapeutics Inc, Newton, MA, USA. de Jonge A; Karyopharm Therapeutics Inc, Newton, MA, USA. Yang F; Karyopharm Therapeutics Inc, Newton, MA, USA. Baloglu E; West Virginia University Cancer Institute, Wheeling Hospital, Wheeling, WV, USA. Shah J; Karyopharm Therapeutics Inc, Newton, MA, USA. KauffmanMG; Karyopharm Therapeutics Inc, Newton, MA, USA. Shacham S; Karyopharm Therapeutics Inc, Newton, MA, USA. Bhatnagar B; West Virginia University Cancer Institute, Wheeling Hospital, Wheeling, WV, USA.
Pokaż więcej
Źródło:
Journal of hematology & oncology [J Hematol Oncol] 2022 Aug 03; Vol. 15 (1), pp. 103. Date of Electronic Publication: 2022 Aug 03.
Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study.
Autorzy:
Maerevoet M; Service Hématologie, Institut Jules Bordet, 1000, Brussels, Belgium. . Zijlstra JM; Amsterdam UMC, Vrije Universiteit, Cancer Center, Amsterdam, Netherlands. Follows G; Addenbrooke's Hospital, Cambridge, UK. Casasnovas RO; Hématologie Clinique and INSERM 1231, CHU Dijon, Dijon, France. Vermaat JSP; LUMC, Leiden, Netherlands. Kalakonda N; University of Liverpool, Liverpool, UK. Goy A; Hackensack University Medical Center, Hackensack, USA. Choquet S; Hôpital Pitié Salpêtrière, Paris, France. Van Den Neste E; Cliniques Universitaires Saint-Luc, Brussels, Belgium. Hill B; Cleveland Clinic, Cleveland, USA. Thieblemont C; APHP, Hemato-oncology, Saint-Louis Hospital, Paris, France.; Diderot University, Paris, France. Cavallo F; University of Torino, Turin, Italy. De la Cruz F; Hospital Universitario Virgen del Rocio, Sevilla, Spain. Kuruvilla J; Princess Margaret Cancer Centre, Toronto, Canada. Hamad N; St. Vincent's Hospital Sydney, Darlinghurst, Australia. Jaeger U; Medical University of Vienna, Vienna, Austria. Caimi P; UH Seidman Cancer Center, Cleveland, USA. Gurion R; Rabin MC, Petah Tiqwa, Israel.; Tel Aviv University, Tel Aviv, Israel. Warzocha K; Instytut Hematologii I Transfuzjologii, Warsaw, Poland. Bakhshi S; Dr. B. R. A. Institute Rotary Cancer Hospital, New Delhi, India. Sancho JM; Hospital Universitari Germans Trias I Pujol, Barcelona, Spain. Schuster M; Stony Brook University Hospital Cancer Center, Stony Brook, USA. Egyed M; Teaching Hospital Mór Kaposi, Kaposvár, Hungary. Offner F; UZ Gent, Gent, Belgium. Vassilakopoulos TP; Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece. Samal P; Institute of Medical Sciences and SUM Hospital, Bhubaneswar, Odisha, India. Ku M; St.Vincent's Hospital Melbourne, Fitzroy, Australia. Ma X; Karyopharm Therapeutics, Newton, USA. Corona K; Karyopharm Therapeutics, Newton, USA. Chamoun K; Karyopharm Therapeutics, Newton, USA. Shah J; Karyopharm Therapeutics, Newton, USA. Shacham S; Karyopharm Therapeutics, Newton, USA. KauffmanMG; Karyopharm Therapeutics, Newton, USA. Canales M; Hospital Universitario La Paz, Madrid, Spain.
Pokaż więcej
Źródło:
Journal of hematology & oncology [J Hematol Oncol] 2021 Jul 16; Vol. 14 (1), pp. 111. Date of Electronic Publication: 2021 Jul 16.
Typ publikacji:
Clinical Trial; Letter; Research Support, Non-U.S. Gov't
Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.
Autorzy:
Mateos MV; Hospital Universitario de Salamanca, Salamanca, Spain. . Gavriatopoulou M; Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. Facon T; CHU Lille Service Des Maladies du Sang, 59000, Lille, France. Auner HW; Imperial College London, London, UK. Leleu X; Department of Hematology, CHU La Miletrie and Inserm CIC 1402, Poitiers, France. Hájek R; Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic. Dimopoulos MA; National and Kapodistrian University of Athens, Athens, Greece. Delimpasi S; General Hospital Evangelismos, Athens, Greece. Simonova M; Institute of Blood Pathology and Transfusion Medicine of NAMS of Ukraine, Lviv, Ukraine. Špička I; Charles University and General Hospital, Prague, Czech Republic. Pour L; University Hospital Brno, Brno, Czech Republic. Kriachok I; National Cancer Institute, Kiev, Ukraine. Pylypenko H; Cherkassy Regional Oncological Center, Cherkassy, Ukraine. Doronin V; City Clinical Hospital #40, Moscow, Russian Federation. Usenko G; City Clinical Hospital No. 4 of Dnipro City Council, Dnipro, Ukraine. Benjamin R; Kings College Hospital NHS Foundation Trust, London, UK. Dolai TK; Nil Ratan Sircar Medical College and Hospital, Kolkata, India. Sinha DK; State Cancer Institute, Indira Gandhi Institute of Medical Sciences, Patna, India. Venner CP; Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada. Garg M; University Hospitals of Leicester NHS Trust, Leicester, UK. Stevens DA; Norton Cancer Institute, St. Matthews Campus, Louisville, KY, USA. Quach H; St Vincent's Hospital, University of Melbourne, Melbourne, VIC, Australia. Jagannath S; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Moreau P; Hotel-Dieu, University Hospital, Nantes, France. Levy M; Baylor University Medical Center, Dallas, TX, USA. Badros AZ; Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, MD, USA. Anderson LD Jr; Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA. Bahlis NJ; Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, USA. Cavo M; Seràgnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy. Chai Y; Karyopharm Therapeutics Inc, Newton, MA, USA. Jeha J; Karyopharm Therapeutics Inc, Newton, MA, USA. Arazy M; Karyopharm Therapeutics Inc, Newton, MA, USA. Shah J; Karyopharm Therapeutics Inc, Newton, MA, USA. Shacham S; Karyopharm Therapeutics Inc, Newton, MA, USA. KauffmanMG; Karyopharm Therapeutics Inc, Newton, MA, USA. Richardson PG; Dana Farber Cancer Institute, Boston, MA, USA. Grosicki S; Medical University of Silesia, Katowice, Poland.
Pokaż więcej
Źródło:
Journal of hematology & oncology [J Hematol Oncol] 2021 Apr 13; Vol. 14 (1), pp. 59. Date of Electronic Publication: 2021 Apr 13.
Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies
